Austin Poole, MD
Medical Oncologist / Hematologist
About Austin Poole, MD
Dr. Austin Poole is a board-certified medical oncologist and hematologist. He sees patients with all hematologic and oncologic diagnosis, but has special interest in genitourinary cancers such as bladder, kidney, prostate and testicular cancers. Further emphasis revolves around blood cancers, leukemia, lymphoma, and multiple myeloma. He attempts to individualize each therapy for the specific circumstances of the patient, integrating their goals and aspirations. He works in a multidisciplinary fashion to optimize cancer care throughout each phase of care, getting multiple inputs and providing the most relevant, informed, and up-to-date therapies.
Clinical Care Expertise
General Medical Oncology
Malignant Hematology/Blood Cancers
Hematology & Oncology, University of Utah, Huntsman Cancer Hospital, Salt Lake City, UT
Internal Medicine, University of Utah School of Medicine, University of Utah Hospital and Clinics, Salt Lake City, UT
Wayne State University School of Medicine, Detroit, MI
Patient Care Philosophy
I strive to support and inform patients in the face of what is often one the most challenging times in their life. At the interface of head and heart, I strive for the best outcomes and to treat each patient how I would want a family member cared for.
American Society of Clinical Oncology
American Society of Hematology
Bailey EB, Tantravahi SK, Wells CE, Straubhar AM, Batten JA, Poole A, Stenehjem DD, Agarwal N. Incidence and severity of hypothyroidism and survival outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs). J Clin Oncol 32, 2014 (suppl; abstr e15580).
Crispin H, Agarwal AM, Salama ME, Tantravahi SK, Merriman J, Straubhar AM, Poole A, Nussenzveig R , Stenehjem DD, Agarwal N. Correlation of tumor programmed death ligand-1 (PD-L1) expression and response to treatment with high-dose interleukin-2 (HD IL-2) in clear cell metastatic renal cell carcinoma (ccmRCC). J Clin Oncol 32, 2014 (suppl; abstr e15584).
Tantravahi SK, Albertson D, Agarwal AM, Straubhar AM, Poole A, Stenehjem DD, Liu T, Agarwal N. Correlation of IMP3 expression and survival in metastatic renal cell carcinoma with sarcomatoid features (SmRCC). J Clin Oncol 32, 2014 (suppl; abstr e15569).
Poole A, Gill DM, Hahn AW, Johnson E, Carroll E, Batten JA, Gupta S, Boucher K, Maughan BL, Agarwal N. Incidence and characterization of antiandrogen withdrawal syndrome (AAWS) after enzalutamide (ENZA) in patients (pts) with metastatic castration-refractory prostate cancer (mCRPC). J Clin Oncol 35, 2017 (suppl 6S; abstract 228).
Carroll E, Gill DM, Poole A, Hahn AW, Bailey EB, Streeter J, Batten JA, Gupta S, Agarwal S, Maughan BL. Genomic diversity between primary tumor tissue and tumor circulating cell-free DNA (cfDNA) in patients (pts) with metastatic prostate cancer. J Clin Oncol 35, 2017 (suppl 6S; abstract 189).
Gill DM, Agarwal N, Hahn AW, Johnson E, Poole A, Carroll E, Boucher KM, Salama ME, Agarwal AM. Impact of circulating tumor cell (CTC) nucleus size on outcomes with abiraterone acetate (AA) therapy in men with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 35, 2017 (suppl 6S; abstract 253).
Poole A, Alva A, Batten J, Agarwal N. Metastatic Castrate Resistant Prostate cancer: Role of Androgen Signaling Inhibitors. In Multidisciplinary Approach to Prostate Cancer.
Necchi AN, Pond GR, Giannatempo P, Di Lorenzo G, Eigl BJ, Locke J, Pal SK, Agarwal N, Poole A, Vaishampayan UN, Niegisch G, Hussain SA, Singh P, Bellmunt J, Sonpavde G. Cisplatin-based first-line therapy for advanced urothelial carcinoma following previous perioperative cisplatin-based therapy. Clin Genitourin Cancer. 2015 Apr;13(2):178-84. doi: 10.1016/j.clgc.2014.08.010. Epub 2014 Sep 23.
Agarwal N, Apolo AB, Tsao CK, Lee KM, Godbold JH, Soto R, Poole A, Gimpel-Tetra K, Lowe N, Oh WK, Galsky MD. Phase Ib/II Trial of Gemcitabine, Cisplatin, plus Lenalidomide as First Line Therapy in Patients with Metastatic Urothelial Carcinoma. Oncologist. 2014 Sep;19(9):915-6. doi: 10.1634/theoncologist.2014-0153. Epub 2014 Jul 22.
Tantravahi SK, Albertson D, Agarwal AM, Ravulapati S, Poole A, Patel SB, Hawatmeh JS, Straubhar AM, Liu T, Stenehjem DD, Agarwal N. Survival Outcomes and Tumor IMP3 Expression in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma. J Oncol. 2015;2015:181926. doi: 10.1155/2015/181926. Epub 2015 Jan 20.
Bailey EB, Tantravahi SK, Poole A, Agarwal AM, Straubhar AM, Batten JA, Patel SB, Wells CE, Stenehjem DD, Agarwal N. Correlation of degree of hypothyroidism with survival outcomes in patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors. Clin Genitourin Cancer. 2015 Jun;13(3):e131-7. doi: 10.1016/j.clgc.2014.11.002. Epub 2014 Nov 15.
Poole A, Girard N, Clayton F, Tantravahi SK. Rapid onset of hemophagocytic lymphohistiocytosis in a patient with refractory chronic lymphocytic leukemia treated with ibrutinib. Leuk Lymphoma. 2016 Oct 17:1-4.
Bailey EB, Merriman J, Maughan BL, Poole A, Tantravahi SK, Agarwal AM, Batten JA, Patel SB, Pal SK, Stenehjem DD, Agarwal N. Effect of treatment dose reductions in the setting of hand-foot syndrome on survival outcomes in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor receptor inhibitors. J Oncol Pharm Practice 0(0) 1–8. doi: 10.1177/1078155217693426. Epub 2017 Jan 1.
Gupta S, Gill D, Poole A, Agarwal N. Systemic Immunotherapy for Urothelial Cancer: Current Trends and Future Directions. Cancers (Basel). 2017 Jan 27;9(2). pii: E15. doi: 10.3390/cancers9020015.
Agarwal N, Hahn AW, Gill DM, Farnham JM, Poole AI, Cannon-Albright L. Independent Validation of Effect of HSD3B1 Genotype on Response to Androgen-Deprivation Therapy in Prostate Cancer. JAMA Oncol. 2017 Feb 16. doi: 10.1001/jamaoncol.2017.0147.
Hahn AW, Gill DM, Poole AI, Nussenzveig, RH Farnham JM, Agarwal N, Cannon-Albright L Germline Variant in HSD3B1 (1245 A > C) and Response to Abiraterone Acetate Plus Prednisone in Men With New-Onset Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2018 Aug;16(4):288-292. doi: 10.1016/j.clgc.2018.03.006. Epub 2018 Mar 27.